




Jabal ChinaAMC Loong Equity Fund

July 2025



Fund Overview



NAV/Unit: 1.0073 **Fund Size**: RO 2.10 Mn

Investment Objective is to maximize total return while lowering overall volatility, seeking to invest in both China onshore and overseas listed equities, whom underlying as both Chinese companies and non-Chinese-companies with significant China market exposure, that will contribute to capital appreciation and/or generate income to the Fund

Fund Details				
Asset Classes	Equities			
Fund Manager	Jabal Asset Management LLC			
Country of Domicile	Sultanate of Oman			
Date of Inception	27 January 2025			
NAV Frequency	Weekly			
Management Fee	2% per annum			
Subscription Fee*	Up to 3%			
Redemption Fee*	2% in the first year. 1% in the second year. 0% in the subsequent years.			
Minimum Subscription	1,000 units, multiples of 100			
Nominal Value	OMR 1.000 *Can be waived for JAM clients			

Monthly Commentary


China's equity market gained ground in July, lifted by calmer geopolitics, rising liquidity, supported by the "anti-involution" drive and expectations of an extension of US-China tariff truce. Domestic indices rallied; CSI delivered +4.2%, HSI +3.6% and the MSCI China all shares returned +5.2% with AI, biopharma, and materials leading. Offshore markets held strong, as investor flows rotated into growth and innovation plays.

The key adjustment to our portfolio was increasing exposure to non-bank Financials (brokers and insurers) - shifting to a neutral stance. This adjustment was underpinned by a stable macroeconomic outlook, sufficient liquidity condition and pro-capital market policy stance. In return, we reduced exposure to some high-dividend stocks, such as Xinhua Winshare Publishing & Media.


At the individual stock level, we added positions in SMIC (HK share), Newborn Town, Qingdao Gon Technology, Qyuns Therapeutics, CATL, and Wuxi Apptec. Among all these names, all holdings except Newborn Town and CATL have performed well. The increased exposure to healthcare stocks was largely driven by bottom-up decision.

Looking ahead, we believe that the regulators will stick to existing measures aimed at stabilizing consumption, housing, infrastructure, while continuing accelerate technological innovation—particularly in AI, robotics, semiconductors, EVs, and biotech. As highlighted in the July Politburo Meeting, effective policy implementation down to details is the key priority in 2H2025, whereas incremental new policy announcement will be data - and time-dependent.

Market sentiment is improving in general. We increase our agility in portfolio construction, to capture surging trends in the realm of technology, new consumption, and globalization. Meanwhile, we retain balanced allocation in defensive and high-dividend-yield plays as well as control export exposure, to mitigate uncertainties surrounding tariffs and geopolitical tensions.



Fund Returns



Key Statistics

Number of holdings	44	
% of largest holding	10.0% - Tencent Holdings Ltd	
Annual std. deviation	10.1%	
Alpha	-3.4%	
Beta	0.7	


Portfolio Characteristics

Ratio	Fund	Benchmark
P/E	15.2x	14.7x
P/B	2.0x	1.6x
Div. Yield	2.2%	2.5%
ROE	14.4%	12.2%
ROA	2.7%	2.2%

Asset Allocation





Active Weights (%)



Sector Allocation (%)

Geographical Breakdown (%)





Top 5 Holdings (%)

Company Name	Sector	Weight	P/E TTM	P/BV	Div Yield TTM
Tencent Holdings Ltd	Communication Services	10.0%	23.2x	4.5x	0.8%
Alibaba Group Holding Ltd	Consumer Discretionary	6.4%	17.9x	2.1x	0.9%
Zijin Mining Group Co Ltd	Materials	5.0%	14.1x	3.5x	2.0%
Contemporary Amperex Technology Co Ltd	Industrials	4.4%	19.9x	4.1x	0.4%
China Merchants Bank Co Ltd	Financials	4.3%	7.6x	1.1x	4.5%

July 2025 3

Disclaimer



Disclaimer

This report is issued by **Jabal Asset Management LLC (JAM)** for informational purposes only and is strictly confidential. It is intended solely for the recipient and may not be reproduced, distributed, or shared, in whole or in part, without the prior written consent of JAM. The information and opinions contained herein are based on publicly available data, and while JAM endeavors to ensure accuracy, completeness, and timeliness, no representation or warranty, express or implied, is made as to their reliability or adequacy.

This report does not constitute an offer, solicitation, or recommendation to buy or sell any securities, financial instruments, or investment products, nor does it provide financial, legal, or tax advice. Recipients are strongly encouraged to seek independent professional advice before making any investment decisions based on the information provided.

Investments in securities involve risks, including the potential loss of principal. Past performance is not indicative of future results. Market conditions, economic factors, and other variables may significantly impact investment outcomes.

The opinions expressed in this report are those of JAM as of the date of publication and are subject to change without notice. JAM and its affiliates may engage in securities trading, provide investment banking services, or offer other financial services to the companies discussed in this report.

JAM shall not be held liable for any direct, indirect, or consequential loss arising from the use of this report or its content.